Skip to main content

Krempa David's Form 4 filing

Eton Pharmaceuticals, Inc.ETON · filed Oct 6, 2026

Accession no.
0001437749-26-032240
Filed
Oct 6, 2026, 4:49 PM ET
Trade date
Oct 2-6, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $229.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Krempa DavidCIK 0001968254Officer (Chief Business Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 2, 2026Common StockMOption exerciseAcquired+10,522–F3–47,547Direct
Oct 6, 2026Common StockSSaleDisposed−4,166$55.07F1,F2−$229,406.2143,381Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 2, 2026Common StockMOption exerciseDisposed−10,522$0.00$021,044Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F2

The shares were sold in multiple trades at prices ranging from $54.915 to $55.135. The price reported above reflects the weighted average sales price.

Referenced by the price of 1 transaction in Table I.

F3

On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025.

Referenced by the price of 1 transaction in Table I.

Remarks

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

Read the full filing on SEC EDGAR (opens in a new tab)